{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.3","upperLimit":"40.1","value":"8.6"},{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG001","lowerLimit":"10.8","upperLimit":"NA","value":"47.2"},{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG002","lowerLimit":"4.0","upperLimit":"NA","value":"32.5"},{"comment":"Follow-up duration too short relative to event accumulation to estimate median and upper limit.","groupId":"OG003","lowerLimit":"9.4","upperLimit":"NA","value":"NA"},{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG004","lowerLimit":"5.1","upperLimit":"NA","value":"8.7"},{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG005","lowerLimit":"0.5","upperLimit":"NA","value":"10.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"Progression-free survival (PFS) per investigator was defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"OG002","title":"Part C"},{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Part D"},{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Part F"}],"paramType":"MEDIAN","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 83 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}